Infertility and In Vitro Fertilization Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Fertil Steril. 2022 Apr;117(4):657-663. doi: 10.1016/j.fertnstert.2022.01.029. Epub 2022 Mar 5.
Pretreatment medications/manipulations are offered to patients with poor ovarian response, aiming to prevent the occurrence of a spontaneous luteinizing hormone surge, increase the number of preantral and antral follicles, synchronize follicular development, and increase oocytes' yield and quality, with the consequent improvement in cycle outcome. Although early small human studies were encouraging, interpretation of the studies is compromised by variations in the type, dose, combination and duration of the pretreatment medications. Whether these measures would serve as valuable tools in the armamentarium for treating patients with poor ovarian response requires further, large prospective studies that should validate the specific mode/combination of pretreatment measures and identify, before initiating ovarian stimulation, the specific characteristics of women who might benefit from the specific regimen.
预处理药物/操作被提供给卵巢反应不良的患者，旨在预防自发性黄体生成素峰的发生，增加窦前卵泡和窦卵泡的数量，使卵泡发育同步，并增加卵母细胞的数量和质量，从而改善周期结局。尽管早期的小型人体研究令人鼓舞，但由于预处理药物的类型、剂量、组合和持续时间存在差异，对这些研究的解释受到影响。这些措施是否会成为治疗卵巢反应不良患者的有效工具，需要进一步进行大型前瞻性研究来验证预处理措施的具体模式/组合，并在开始卵巢刺激前确定可能从特定方案中受益的女性的具体特征。
